Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Pharmaceutical Drug Import for Clinical Trials to Russia (June and Q1 – Q2 2020)

Friday, July 31, 2020

Between January and June 2020, Russia imported 12.2 bln RUB worth of pharmaceutical drugs for clinical trials (CT) (customs clearance and VAT included), which is in monetary terms (rubles) 49% higher than in 2019. The dynamics in physical terms (units) are also positive, +40%, with the import volume of 472 thousand units.

Russia imported 505 pharmaceutical trademarks between January and June 2020 against 444 in the first half of 2019. Placebo products accounted for 34% of the import in physical terms (against 40% in 2019) and for 18% in monetary terms (16% in 2019). The total number of the imported placebo products was 181 (155 in 2019).

Eye drops Ikervis (Ciclosporin) by Santen are still the most import pharmaceutical drug for CT in physical terms, with 49.5 thousand units. MK-3475 (Pembrolizumab) by MSD remains the most imported pharmaceutical in monetary terms (11.6 thousand units).

Selpercatinib by Eli Lilly accounts for the biggest import volume in monetary terms among the new pharmaceutical drugs, which Russia started importing in Q2 2020. Two parallel studies are currently underway, both multicenter, randomized, open-label, phase III trials to compare the drug with alternative treatment regimens in patients with advanced medullary thyroid cancer, as well as advanced or metastatic non-small cell lung cancer. 16 clinical centers and 46 patients are involved in the study. The company received research approvals in February 2020, with imports starting in April 2020.

As for import volume in physical terms, ND0612 by NeuroDerm (Israel) is the leader. The product is a combination of Levodopa and Carbidopa in solution for continuous subcutaneous administration. It is currently undergoing a multicenter, randomized, double-blind phase III study, controlled by active drug, to study the efficacy, safety and tolerability of the drug in patients with Parkinson's disease. 25 people at 6 medical centers are involved in the study. The CTs were permitted back in 2017 to be later suspended and resumed only in 2020.

Dynamics of pharmaceutical drug import volumes for clinical trials (CT) to Russia (2016 – 2019, Q1 – Q2 2020), free circulation prices (customs clearance and VAT included)